CN110916200A - 一种降尿酸组合物及其制备方法 - Google Patents
一种降尿酸组合物及其制备方法 Download PDFInfo
- Publication number
- CN110916200A CN110916200A CN201911210855.6A CN201911210855A CN110916200A CN 110916200 A CN110916200 A CN 110916200A CN 201911210855 A CN201911210855 A CN 201911210855A CN 110916200 A CN110916200 A CN 110916200A
- Authority
- CN
- China
- Prior art keywords
- powder
- parts
- uric acid
- inulin
- gamma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 73
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims abstract description 73
- 229940116269 uric acid Drugs 0.000 title claims abstract description 73
- 239000000203 mixture Substances 0.000 title claims abstract description 56
- 230000001603 reducing effect Effects 0.000 title claims abstract description 56
- 238000002360 preparation method Methods 0.000 title claims description 14
- 239000000843 powder Substances 0.000 claims abstract description 261
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 58
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 38
- 241000251511 Holothuroidea Species 0.000 claims abstract description 32
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 32
- 244000182216 Mimusops elengi Species 0.000 claims abstract description 32
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 32
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 32
- 244000000626 Daucus carota Species 0.000 claims abstract description 31
- 235000002767 Daucus carota Nutrition 0.000 claims abstract description 31
- 108010028690 Fish Proteins Proteins 0.000 claims abstract description 31
- 235000009467 Carica papaya Nutrition 0.000 claims abstract description 30
- 241001264174 Cordyceps militaris Species 0.000 claims abstract description 30
- 235000020197 coconut milk Nutrition 0.000 claims abstract description 30
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 30
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 30
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims abstract description 29
- 229920001202 Inulin Polymers 0.000 claims abstract description 29
- 240000008790 Musa x paradisiaca Species 0.000 claims abstract description 29
- 235000018290 Musa x paradisiaca Nutrition 0.000 claims abstract description 29
- 241001506047 Tremella Species 0.000 claims abstract description 29
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims abstract description 29
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 29
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 29
- 229940029339 inulin Drugs 0.000 claims abstract description 29
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims abstract description 27
- 239000002994 raw material Substances 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 15
- 238000004806 packaging method and process Methods 0.000 claims abstract description 12
- 239000006187 pill Substances 0.000 claims abstract description 10
- 238000002156 mixing Methods 0.000 claims abstract description 8
- 230000008569 process Effects 0.000 claims abstract description 8
- 238000007873 sieving Methods 0.000 claims abstract description 8
- 244000269722 Thea sinensis Species 0.000 claims abstract 9
- 241000219173 Carica Species 0.000 claims description 28
- 241000229143 Hippophae Species 0.000 claims description 26
- 238000011049 filling Methods 0.000 claims description 7
- 238000007789 sealing Methods 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 34
- 239000008280 blood Substances 0.000 abstract description 34
- 230000000694 effects Effects 0.000 abstract description 34
- 230000036039 immunity Effects 0.000 abstract description 15
- 210000003734 kidney Anatomy 0.000 abstract description 14
- 210000000952 spleen Anatomy 0.000 abstract description 10
- 235000013399 edible fruits Nutrition 0.000 abstract description 6
- 235000012907 honey Nutrition 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 240000006432 Carica papaya Species 0.000 abstract 2
- 240000000950 Hippophae rhamnoides Species 0.000 abstract 1
- 241001122767 Theaceae Species 0.000 description 23
- 210000004185 liver Anatomy 0.000 description 10
- 230000001737 promoting effect Effects 0.000 description 10
- 201000001431 Hyperuricemia Diseases 0.000 description 9
- 230000017531 blood circulation Effects 0.000 description 8
- 230000036772 blood pressure Effects 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 210000002216 heart Anatomy 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 230000029142 excretion Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 238000005728 strengthening Methods 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 201000005569 Gout Diseases 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 241000190633 Cordyceps Species 0.000 description 3
- 208000001647 Renal Insufficiency Diseases 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- -1 amino oligosaccharide Chemical class 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 235000001465 calcium Nutrition 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 201000006370 kidney failure Diseases 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000000913 Kidney Calculi Diseases 0.000 description 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- OEYQBKYISMRWQB-UHFFFAOYSA-N Santal Chemical compound C=1C(OC)=CC(O)=C(C2=O)C=1OC=C2C1=CC=C(O)C(O)=C1 OEYQBKYISMRWQB-UHFFFAOYSA-N 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 2
- 229960002529 benzbromarone Drugs 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 150000001746 carotenes Chemical class 0.000 description 2
- 235000005473 carotenes Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 208000006750 hematuria Diseases 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000004199 lung function Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- SBZWTSHAFILOTE-SOUVJXGZSA-N (2R,3S,4S)-leucocyanidin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3[C@H](O)[C@@H]2O)=CC=C(O)C(O)=C1 SBZWTSHAFILOTE-SOUVJXGZSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 description 1
- 108010071840 Cytosol nonspecific dipeptidase Proteins 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 101000821903 Homo sapiens Solute carrier family 22 member 12 Proteins 0.000 description 1
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- IPMYMEWFZKHGAX-UHFFFAOYSA-N Isotheaflavin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1C(O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-UHFFFAOYSA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- HMXJLDJMSRBOCV-UHFFFAOYSA-N Leucocyanidin Natural products OC1C(OC2C(O)C(Oc3cc(O)cc(O)c23)c4ccc(O)c(O)c4)c5c(O)cc(O)cc5OC1c6ccc(O)c(O)c6 HMXJLDJMSRBOCV-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 206010038419 Renal colic Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 102100021495 Solute carrier family 22 member 12 Human genes 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- UXRMWRBWCAGDQB-UHFFFAOYSA-N Theaflavin Natural products C1=CC(C2C(CC3=C(O)C=C(O)C=C3O2)O)=C(O)C(=O)C2=C1C(C1OC3=CC(O)=CC(O)=C3CC1O)=CC(O)=C2O UXRMWRBWCAGDQB-UHFFFAOYSA-N 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000005904 anticancer immunity Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229940108928 copper Drugs 0.000 description 1
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 description 1
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- SBZWTSHAFILOTE-UHFFFAOYSA-N leucocianidol Natural products OC1C(O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 SBZWTSHAFILOTE-UHFFFAOYSA-N 0.000 description 1
- 229940086558 leucocyanidin Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 235000014786 phosphorus Nutrition 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical group 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 235000014620 theaflavin Nutrition 0.000 description 1
- IPMYMEWFZKHGAX-ZKSIBHASSA-N theaflavin Chemical compound C1=C2C([C@H]3OC4=CC(O)=CC(O)=C4C[C@H]3O)=CC(O)=C(O)C2=C(O)C(=O)C=C1[C@@H]1[C@H](O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-ZKSIBHASSA-N 0.000 description 1
- 229940026509 theaflavin Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000003424 uricosuric effect Effects 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/01—Instant products; Powders; Flakes; Granules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/10—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/616—Echinodermata, e.g. starfish, sea cucumbers or sea urchins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Marine Sciences & Fisheries (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种降尿酸组合物,原料组成按重量份计,包括:菊粉30‑70份、椰浆粉25‑45份、胡萝卜粉1‑4份、青木瓜粉1‑5份、香蕉粉1‑4份、银耳粉1‑4份、壳寡糖0.5‑3份、γ‑氨基丁酸0.1‑3份、茶多酚0.1‑3份、沙棘粉0.1‑3份、枸杞粉0.1‑2份、蛹虫草粉0.1‑2份、海参粉0.1‑1份。将上述重量份的菊粉、椰浆粉、胡萝卜粉、青木瓜粉、香蕉果粉、银耳粉、壳寡糖、γ‑氨基丁酸、茶多酚、海洋鱼蛋白肽、枸杞粉、蛹虫草粉、海参肽粉混合均匀后过100目筛,得到降尿酸组合物;然后在降尿酸组合物中加入炼蜜,采用常规工艺制成丸剂;再将制得的丸剂按每袋10克装入包装袋中并封口。本发明可有效降低血尿酸含量,强肾健脾、梳经通络、提高人体免疫力,且无毒副作用。
Description
技术领域
本发明涉及医药保健品技术领域,具体为一种降尿酸组合物及其制备方法。
背景技术
高尿酸症是指在正常嘌呤饮食状态下,非同日两次空腹血尿酸水平男性高于420μmol/L,女性高于360μmol/L,即称为高尿酸血症,随着生活水平的提高和饮食习惯的改变,高尿酸血症和痛风的发病率逐渐升高。高尿酸血症是由于嘌呤代谢絮乱和/或尿酸***障碍而导致血尿酸超过正常值的一种疾病,临床上不表现任何症状。而当人体长期处于高尿酸血症的情况下,尿酸即以钠盐的形式沉淀在关节、软组织、软骨和肾脏中,引起人体器官和组织病变,导致痛风,引发严重的并发症,包括痛风性关节炎、痛风性肾脏病变、痛风性肾结石、痛风性高血压病等,病人出现关节痛、肾绞痛或血尿等症状。
现有的治疗高尿酸血症的方法主要是使用排尿酸药,排尿酸药主要包括苯溴马隆、磺吡酮等,该类药物可以阻止肾小管对尿酸的重吸收,增加尿酸的排出,从而起到降低人体体血尿酸水平的作用,但是苯溴马隆一般用于轻度肾功能不全的高尿酸血症患者,此种药物副作用较大,会导致尿酸结石,肝肾结石;磺吡酮只能用于肾功能正常患者,但会导致肝损伤等副作用。
因此,亟需研发一种可有效降低血尿酸含量的同时,具有强肾健脾、益气清肠、提高免疫力、抗氧化的降尿酸组合物。
发明内容
本发明针对上述现有技术存在的问题,提供一种既可有效降低血尿酸含量,又可强肾健脾、益气清肠、提高免疫力、抗氧化的降尿酸组合物。
为实现以上目的,本发明通过以下技术方案予以实现:一种降尿酸组合物,原料组成按重量份计,包括:
菊粉30-70份、椰浆粉25-45份、胡萝卜粉1-4份、青木瓜粉1-5份、香蕉粉1-4份、银耳粉1-4份、壳寡糖0.5-3份、γ-氨基丁酸0.1-3份、茶多酚0.1-3份、沙棘粉0.1-3份、枸杞粉0.1-2份、蛹虫草粉0.1-2份、海参粉0.1-1份。
进一步地:还包括重量份为10-30份海洋鱼蛋白肽。
进一步地:原料组成按重量份计,包括:菊粉50份、椰浆粉36份、胡萝卜粉2.7份、青木瓜粉2.9份、香蕉粉2.7份、银耳粉2.7份、壳寡糖0.7份、γ-氨基丁酸0.5份、茶多酚0.5份、沙棘粉0.5份、枸杞粉0.2份、蛹虫草粉0.2份、海参粉0.1份、海洋鱼蛋白肽20份。
进一步地:原料组成按重量份计,包括:菊粉55份、椰浆粉34份、胡萝卜粉2份、青木瓜粉2.5份、香蕉粉2.5份、银耳粉2.2份、壳寡糖0.5份、γ-氨基丁酸0.4份、茶多酚0.6份、沙棘粉0.6份、枸杞粉0.25份、蛹虫草粉0.15份、海参粉0.15份、海洋鱼蛋白肽25份。
进一步地:原料组成按重量份计,包括:菊粉58份、椰浆粉35份、胡萝卜粉2.5份、青木瓜粉2.6份、香蕉粉2.6份、银耳粉2.6份、壳寡糖0.6份、γ-氨基丁酸0.3份、茶多酚0.4份、沙棘粉0.7份、枸杞粉0.23份、蛹虫草粉0.3份、海参粉0.12份、海洋鱼蛋白肽19份。
进一步地:原料组成按重量份计,包括:菊粉48份、椰浆粉39份、胡萝卜粉2.8份、青木瓜粉3份、香蕉粉2.75份、银耳粉2.8份、壳寡糖0.8份、γ-氨基丁酸0.45份、茶多酚0.55份、沙棘粉0.65份、枸杞粉0.3份、蛹虫草粉0.25份、海参粉0.14份、海洋鱼蛋白肽22份。
进一步地:原料组成按重量份计,包括:菊粉49份、椰浆粉37份、胡萝卜粉2.6份、青木瓜粉2.9份、香蕉粉2.8份、银耳粉2.75份、壳寡糖0.75份、γ-氨基丁酸0.48份、茶多酚0.45份、沙棘粉0.55份、枸杞粉0.28份、蛹虫草粉0.35份、海参粉0.17份、海洋鱼蛋白肽28份。
一种降尿酸组合物的制备方法,包括以下步骤:
1)按重量份取菊粉、椰浆粉、胡萝卜粉、青木瓜粉、香蕉粉、银耳粉、壳寡糖、γ-氨基丁酸、茶多酚、海洋鱼蛋白肽、枸杞粉、蛹虫草粉、海参粉混合均匀后过筛,得到降尿酸组合物;
2)在步骤1)中的所述降尿酸组合物中可加入辅料,采用常规工艺制成临床上可接受的剂型;
3)将步骤2)中的制得的临床剂型按每袋8-12克装入包装袋中并封口。
进一步地:步骤2)中所述的剂型为粉剂、丸剂、颗粒剂。
进一步地:步骤3)中的临床剂型按每袋10克装入包装袋中。
本发明的有益效果:
本降尿酸组合物通过选用具有降血糖、降血脂、降血压、强肾健脾、通经络、预防心血管疾病、降低血糖活性、抗氧化、提高免疫力等功效的中药按一定配比配合使用,其所含的菊粉、椰浆粉、胡萝卜粉、γ-氨基丁酸、海参肽粉、枸杞粉等具有可降血糖、降血脂、降血压功效,胡萝卜粉能够促进肾上腺素的合成,有助于促进人体新陈代谢,促进血液通畅,有助于增加尿酸的***,降低体内尿酸的含量,银耳粉可强心健脑、益气清肠、补脾开胃,使高血脂病人的血胆固醇和甘油三脂下降,增强机体免疫能力,蛹虫草粉等可以消除疲劳,调节人体内分泌,帮助清除自由基,防止皮肤衰老,提高利尿功效,上述多种原料按一定配比组合,多种功效协同增效,不仅能养肝补肾,明显提高人体免疫力,促进血液通畅的同时,降脂活血,使血脂粘度降低,气血通畅而提高尿酸代谢的速率,从而有效降低血尿酸的含量,且没有毒副作用。
具体实施方式
下面将结合本发明实施例,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
根据本发明的一个方面,一种降尿酸组合物,其原料组成按重量份计,包括以下组分:菊粉30-70份、椰浆粉25-45份、胡萝卜粉1-4份、青木瓜粉1-5份、香蕉粉1-4份、银耳粉1-4份、壳寡糖0.5-3份、γ-氨基丁酸0.1-3份、茶多酚0.1-3份、沙棘粉0.1-3份、海洋鱼蛋白肽10-30份、枸杞粉0.1-2份、蛹虫草粉0.1-2份、海参粉0.1-1份。
本发明所用原料成份的功效和作用:
菊粉:降低血脂水平,促进脂肪从大便***,降低血糖、促进矿物质的吸收、护肝、使肠道双歧杆菌增多,调节肠道菌群;
椰浆粉:椰浆粉含有适量脂肪、大量植物蛋白以及17种人体所需的氨基酸、5种维生素和锌、钙、铁等微量元素,椰浆粉可以降低人体血脂水平,预防高血脂症,从而起到对心血管的保健,促进人体新陈代谢,避免黑色素沉淀,美白肌肤,提高人体免疫力及促进消化和吸收,令人血液通畅,肌肤红润;
胡萝卜粉:胡萝卜含有懈皮素、山标酚,能增加冠状动脉血流量、降低血脂,促进肾上腺素的合成,还有降压、强心作用,可降血压,益肝明目、增强免疫功能、健脾除助生长;
壳寡糖:壳寡糖是一种带有正电荷阳离子碱性氨基低聚糖,是动物性纤维素,对人体的免疫调节、降血脂、调节血糖、抗肿瘤、改善肝脏和心肺功能及其他多种生理功能有着重要作用,防止热能过剩,控制肥胖,维护肠道菌群的平衡,有益于长寿;
香蕉粉:香蕉含有钙、钾,可使过多的钠离子排出,使血压降低,还含有Lectin,Lectin是一种蛋白质,在免疫***上,可以进一步刺激T细胞分化,增强人体的抗癌的免疫力,而且它在肠胃道会直接被吸收,不像其他蛋白质会被分解,所以更具抗癌功效,还富含纤维,预防便秘,可刺激肠胃蠕动,增加粪便体积,帮助排便;
青木瓜粉:青木瓜含丰富的木瓜酵素、木瓜蛋白酶、凝乳蛋白酶、胡萝卜素等,并富含十七种以上氨基酸及多种营养元素,对脾胃虚弱、食欲不振、关节疼痛、肢体麻木等具有良好效果,梳筋通络,减肥,护肤美白;
银耳粉:银耳能入肺、脾胃、肾、大肠五经,可生津防噪、滋阴润肺、强心健脑,益气清肠、补脾开胃、平肝安神,改善心、肺功能,使部分高血脂病人的血胆固醇和甘油三脂下降,增强机体免疫能力,抑制癌细胞的生长;
沙棘粉:沙棘含有沙棘黄酮及其他活性物质具有降低高血压、软化血管,改善血液循环等作用,对缺血性脑血管病有防治和缓解作用,具有改善大脑供血供氧作用,沙棘中的酚类化合物能够抗氧化,可以使许多生物活性物质保持其活性,沙棘中的生物活性成分白花青素、苦木素、香豆素、5-羟色胺等可以抗肿瘤,可以直接抑制癌细胞作用以及阻断致癌因素的作用。沙棘油具有防癌、抗癌的作用,沙棘还可以清除人体内的自由基,提高免疫功能,对于提高人体的抗病能力,延缓人体衰老有着重要作用。另外,沙棘中的多种生物营养成份对护理皮肤,防皱抗衰也有很好的作用;
γ-氨基丁酸:促进脑的活化性,健脑益智,抗癫痫,促进睡眠,美容润肤,延缓脑衰老机能,能补充人体抑制性神经递质,具有良好的降血压功效;
茶多酚:有助于抑制心血管疾病,茶多酚中的儿茶素ECG和EGC及其氧化物产物茶黄素等,有助于使动脉粥样化斑块的斑状增生受到抑制,使形成血凝黏度增强的纤维蛋白原降低,凝血变清,从而抑制动脉粥样硬化,有助于延缓衰老,美容护肤;
海参粉:海参粉含有钒、锰、钾、铜、尼克酸、牛磺酸等可以影响体内脂肪的代谢过程,具有防止脂肪肝形成,调节血脂的作用,能够预防心血管病,降血压,海参粉中的酸性粘多糖具有在机体中降低血糖活性,抑制糖尿病发生的作用,海参粉中的丰富胶原蛋白质占了90%、精氨酸、硫酸软骨素、磷、硒、烟酸、硅等具有延年益寿、消除疲劳、防治皮肤衰老、美容等功效;
蛹虫草粉:蛹虫草富含虫草酸、虫草菌素和虫草多糖等物质,传统中医认为,虫草酸入肺肾二经,既能补肺阴,又能补肾阳,主治肾虚,阳痿遗精,腰膝酸痛,病后虚弱,久咳虚弱,劳咳痰血,自汗盗汗等,是唯一的一种能同时平衡、调节阴阳的中药,能够具有调节全身功能、提高免疫能力、增强巨噬细胞的吞噬功能,促进抗体的形成的作用,可以显著的提高患有高尿酸血症患者的利尿和身体免疫力,预防肾功能衰竭;
枸杞粉:枸杞性甘、平,归肝肾经,具有滋补肝肾,养肝明目的功效,现代医学研究表明,它含有胡萝卜素、甜菜碱、维生素A、维生素B1、维生素B2、维生素C和钙、磷、铁等,具有增加白细胞活性、促进肝细胞新生的药理作用,近代药理实验表明:枸杞子具有增强机体免疫功能,抑制肿瘤,降血糖,降血脂,抗疲劳等功能作用;
海洋鱼蛋白肽:海洋鱼蛋白肽具有迅速缓解机体疲劳、增强机体免疫力;还具有显著降低尿酸水平的作用。
海洋鱼蛋白肽降低血尿酸值主要有三个作用机制,一是海洋鱼蛋白肽中的咮唑化合物能够促进次黄嘌呤磷酸核糖转移酶表达,降低次黄嘌呤和鸟嘌呤含量;二是促进乳酸脱氢酶的表达,催化丙酮酸和乳酸盐的相互转化,激活URAT1,促进尿酸的再吸收和尿***;三是海洋鱼蛋白肽被血液吸收,通过肌肽酶水解成71-甲基组氨酸和P-丙氨酸,通过质子缓冲能力,稳定尿液的pH,提高尿酸的溶解度并加速尿酸***。
制备实施例
实施例1
一种降尿酸组合物,原料组成按重量份计,包括:菊粉50份、椰浆粉36份、胡萝卜粉2.7份、青木瓜粉2.9份、香蕉粉2.7份、银耳粉2.7份、壳寡糖0.7份、γ-氨基丁酸0.5份、茶多酚0.5份、沙棘粉0.5份、枸杞粉0.2份、蛹虫草粉0.2份、海参粉0.1份、海洋鱼蛋白肽20份。
上述降尿酸组合物的制备方法,包括以下步骤:
1)将上述重量份的菊粉、椰浆粉、胡萝卜粉、青木瓜粉、香蕉果粉、银耳粉、壳寡糖、γ-氨基丁酸、茶多酚、海洋鱼蛋白肽、枸杞粉、蛹虫草粉、海参肽粉混合均匀后过100目筛,得到降尿酸组合物;
2)将步骤1)中的尿酸组合物采用常规工艺制成散剂;
3)将步骤2)中的散剂按每袋10克装入包装袋中并封口。
实施例2
一种降尿酸组合物,原料组成按重量份计,包括:菊粉55份、椰浆粉34份、胡萝卜粉2份、青木瓜粉2.5份、香蕉粉2.5份、银耳粉2.2份、壳寡糖0.5份、γ-氨基丁酸0.4份、茶多酚0.6份、沙棘粉0.6份、枸杞粉0.25份、蛹虫草粉0.15份、海参粉0.15份、海洋鱼蛋白肽25份。
上述降尿酸组合物的制备方法,包括以下步骤:
1)将上述重量份的菊粉、椰浆粉、胡萝卜粉、青木瓜粉、香蕉果粉、银耳粉、壳寡糖、γ-氨基丁酸、茶多酚、海洋鱼蛋白肽、枸杞粉、蛹虫草粉、海参肽粉混合均匀后过100目筛,得到降尿酸组合物;
2)在步骤1)中的降尿酸组合物中加入炼蜜,采用常规工艺制成丸剂;
3)将步骤2)中制得的丸剂按每袋10克装入包装袋中并封口。
实施例3
一种降尿酸组合物,原料组成按重量份计,包括:菊粉58份、椰浆粉35份、胡萝卜粉2.5份、青木瓜粉2.6份、香蕉粉2.6份、银耳粉2.6份、壳寡糖0.6份、γ-氨基丁酸0.3份、茶多酚0.4份、沙棘粉0.7份、枸杞粉0.23份、蛹虫草粉0.3份、海参粉0.12份、海洋鱼蛋白肽19份。
上述降尿酸组合物的制备方法,包括以下步骤:
1)将上述重量份的菊粉、椰浆粉、胡萝卜粉、青木瓜粉、香蕉果粉、银耳粉、壳寡糖、γ-氨基丁酸、茶多酚、海洋鱼蛋白肽、枸杞粉、蛹虫草粉、海参肽粉混合均匀后过100目筛,得到降尿酸组合物;
2)将步骤1)中的尿酸组合物采用常规工艺制成散剂;
3)将步骤2)中的散剂按每袋10克装入包装袋中并封口。
实施例4
一种降尿酸组合物,原料组成按重量份计,包括:菊粉48份、椰浆粉39份、胡萝卜粉2.8份、青木瓜粉3份、香蕉粉2.75份、银耳粉2.8份、壳寡糖0.8份、γ-氨基丁酸0.45份、茶多酚0.55份、沙棘粉0.65份、枸杞粉0.3份、蛹虫草粉0.25份、海参粉0.14份、海洋鱼蛋白肽22份。
上述降尿酸组合物的制备方法,包括以下步骤:
1)将上述重量份的菊粉、椰浆粉、胡萝卜粉、青木瓜粉、香蕉果粉、银耳粉、壳寡糖、γ-氨基丁酸、茶多酚、海洋鱼蛋白肽、枸杞粉、蛹虫草粉、海参肽粉混合均匀后过100目筛,得到降尿酸组合物;
2)在步骤1)中的降尿酸组合物中加入炼蜜,采用常规工艺制成丸剂;
3)将步骤2)中制得的丸剂按每袋10克装入包装袋中并封口。
实施例5
一种降尿酸组合物,原料组成按重量份计,包括:菊粉49份、椰浆粉37份、胡萝卜粉2.6份、青木瓜粉2.9份、香蕉粉2.8份、银耳粉2.75份、壳寡糖0.75份、γ-氨基丁酸0.48份、茶多酚0.45份、沙棘粉0.55份、枸杞粉0.28份、蛹虫草粉0.35份、海参粉0.17份、海洋鱼蛋白肽28份。
上述降尿酸组合物的制备方法,包括以下步骤:上述降尿酸组合物的制备方法,包括以下步骤:
1)将上述重量份的菊粉、椰浆粉、胡萝卜粉、青木瓜粉、香蕉果粉、银耳粉、壳寡糖、γ-氨基丁酸、茶多酚、海洋鱼蛋白肽、枸杞粉、蛹虫草粉、海参肽粉混合均匀后过100目筛,得到降尿酸组合物;
2)在步骤1)中的降尿酸组合物中加入炼蜜,采用常规工艺制成丸剂;
3)将步骤2)中制得的丸剂按每袋10克装入包装袋中并封口。
本发明的降尿酸组组合物的服用方法为:口服,每日1-2次,每次一袋(规格:10g/袋),每次用水冲调,水的用量为:降尿酸组合物:水=1:8-10。
本发明降尿酸组合物的原料选用具有益肝明目、梳筋通络、强心健脑、补脾开胃等功效的原料组分配合使用,既能保护肾脏、滋养肾脏,能够明显提高人体免疫力,又能降血脂、降血糖,可防止血脂过高阻碍体内尿酸代谢,更容易造成高尿酸血症,降脂活血,促进血液通畅,加速尿酸***,有效降低尿酸含量,明显改善痛风症状,且无毒副作用,无论是肾功能正常者还是肾功能不全患者均可使用。
以上内容是结合具体的优选实施方式对本发明所作的进一步详细说明,不能认定本发明的具体实施只局限于这些说明。对于本发明所属技术领域的普通技术人员来说,在不脱离本发明构思的前提下,还可以做出若干简单推演或替换,都应当视为属于本发明的保护范围。
Claims (10)
1.一种降尿酸组合物,其特征在于:原料组成按重量份计,包括:
菊粉30-70份、椰浆粉25-45份、胡萝卜粉1-4份、青木瓜粉1-5份、香蕉粉1-4份、银耳粉1-4份、壳寡糖0.5-3份、γ-氨基丁酸0.1-3份、茶多酚0.1-3份、沙棘粉0.1-3份、枸杞粉0.1-2份、蛹虫草粉0.1-2份、海参粉0.1-1份。
2.根据权利要求1所述一种降尿酸组合物,其特征在于:还包括重量份为10-30份海洋鱼蛋白肽。
3.根据权利要求2所述一种降尿酸组合物,其特征在于:原料组成按重量份计,包括:菊粉50份、椰浆粉36份、胡萝卜粉2.7份、青木瓜粉2.9份、香蕉粉2.7份、银耳粉2.7份、壳寡糖0.7份、γ-氨基丁酸0.5份、茶多酚0.5份、沙棘粉0.5份、枸杞粉0.2份、蛹虫草粉0.2份、海参粉0.1份、海洋鱼蛋白肽20份。
4.根据权利要求2所述一种降尿酸组合物,其特征在于:原料组成按重量份计,包括:菊粉55份、椰浆粉34份、胡萝卜粉2份、青木瓜粉2.5份、香蕉粉2.5份、银耳粉2.2份、壳寡糖0.5份、γ-氨基丁酸0.4份、茶多酚0.6份、沙棘粉0.6份、枸杞粉0.25份、蛹虫草粉0.15份、海参粉0.15份、海洋鱼蛋白肽25份。
5.根据权利要求2所述一种降尿酸组合物,其特征在于:原料组成按重量份计,包括:菊粉58份、椰浆粉35份、胡萝卜粉2.5份、青木瓜粉2.6份、香蕉粉2.6份、银耳粉2.6份、壳寡糖0.6份、γ-氨基丁酸0.3份、茶多酚0.4份、沙棘粉0.7份、枸杞粉0.23份、蛹虫草粉0.3份、海参粉0.12份、海洋鱼蛋白肽19份。
6.根据权利要求2所述一种降尿酸组合物,其特征在于:原料组成按重量份计,包括:菊粉48份、椰浆粉39份、胡萝卜粉2.8份、青木瓜粉3份、香蕉粉2.75份、银耳粉2.8份、壳寡糖0.8份、γ-氨基丁酸0.45份、茶多酚0.55份、沙棘粉0.65份、枸杞粉0.3份、蛹虫草粉0.25份、海参粉0.14份、海洋鱼蛋白肽22份。
7.根据权利要求2所述一种降尿酸组合物,其特征在于:原料组成按重量份计,包括:菊粉49份、椰浆粉37份、胡萝卜粉2.6份、青木瓜粉2.9份、香蕉粉2.8份、银耳粉2.75份、壳寡糖0.75份、γ-氨基丁酸0.48份、茶多酚0.45份、沙棘粉0.55份、枸杞粉0.28份、蛹虫草粉0.35份、海参粉0.17份、海洋鱼蛋白肽28份。
8.一种降尿酸组合物的制备方法,其特征在于:包括以下步骤:
1)按重量份取菊粉、椰浆粉、胡萝卜粉、青木瓜粉、香蕉粉、银耳粉、壳寡糖、γ-氨基丁酸、茶多酚、海洋鱼蛋白肽、枸杞粉、蛹虫草粉、海参粉混合均匀后过筛,得到降尿酸组合物;
2)在步骤1)中的所述降尿酸组合物中可加入辅料,采用常规工艺制成临床上可接受的剂型;
3)将步骤2)中的制得的临床剂型按每袋8-12克装入包装袋中并封口。
9.根据权利要求8所述一种降尿酸组合物的制备方法,其特征在于:步骤2)中所述的剂型为粉剂、丸剂、颗粒剂。
10.根据权利要求8所述一种降尿酸组合物的制备方法,其特征在于:步骤3)中的临床剂型按每袋10克装入包装袋中。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911210855.6A CN110916200A (zh) | 2019-12-02 | 2019-12-02 | 一种降尿酸组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911210855.6A CN110916200A (zh) | 2019-12-02 | 2019-12-02 | 一种降尿酸组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110916200A true CN110916200A (zh) | 2020-03-27 |
Family
ID=69848382
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911210855.6A Pending CN110916200A (zh) | 2019-12-02 | 2019-12-02 | 一种降尿酸组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110916200A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113679051A (zh) * | 2021-08-24 | 2021-11-23 | 广州丹荟生物科技有限公司 | 一种牡丹多肽粉、其固体饮料及应用 |
CN114209049A (zh) * | 2021-12-20 | 2022-03-22 | 金日制药(中国)有限公司 | 一种海洋益生元组合物及其制备方法和用途 |
CN115104734A (zh) * | 2022-07-19 | 2022-09-27 | 中山市嘉信医疗器械有限公司 | 一种降尿酸保健食品及其制备方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040242491A1 (en) * | 2003-05-30 | 2004-12-02 | Lytone Enterpprise Inc. | Composition containing dipeptide of histidine and alanine for reducing uric acid and method for reducing uric acid using the dipeptide |
CN101878908A (zh) * | 2010-06-28 | 2010-11-10 | 崔晓廷 | 沙棘果提取物组合保健品及其制备方法 |
CN103271177A (zh) * | 2013-03-19 | 2013-09-04 | 天津科技大学 | 一种富含γ-氨基丁酸的保健香茶及制备方法 |
CN104473977A (zh) * | 2014-11-18 | 2015-04-01 | 广东省微生物研究所 | 一种蛹虫草水提物、制备方法及其应用 |
CN108391774A (zh) * | 2018-05-25 | 2018-08-14 | 张瑞雪 | 一种抗痛风的功能饮料及其制备方法 |
CN108420825A (zh) * | 2018-03-28 | 2018-08-21 | 青岛大学 | 壳寡糖在制备抗痛风药物中的应用 |
CN109464563A (zh) * | 2018-12-26 | 2019-03-15 | 广东微量元素生物科技有限公司 | 一种可调节人体尿酸的植物提取组合物及其制备方法 |
-
2019
- 2019-12-02 CN CN201911210855.6A patent/CN110916200A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040242491A1 (en) * | 2003-05-30 | 2004-12-02 | Lytone Enterpprise Inc. | Composition containing dipeptide of histidine and alanine for reducing uric acid and method for reducing uric acid using the dipeptide |
CN101878908A (zh) * | 2010-06-28 | 2010-11-10 | 崔晓廷 | 沙棘果提取物组合保健品及其制备方法 |
CN103271177A (zh) * | 2013-03-19 | 2013-09-04 | 天津科技大学 | 一种富含γ-氨基丁酸的保健香茶及制备方法 |
CN104473977A (zh) * | 2014-11-18 | 2015-04-01 | 广东省微生物研究所 | 一种蛹虫草水提物、制备方法及其应用 |
CN108420825A (zh) * | 2018-03-28 | 2018-08-21 | 青岛大学 | 壳寡糖在制备抗痛风药物中的应用 |
CN108391774A (zh) * | 2018-05-25 | 2018-08-14 | 张瑞雪 | 一种抗痛风的功能饮料及其制备方法 |
CN109464563A (zh) * | 2018-12-26 | 2019-03-15 | 广东微量元素生物科技有限公司 | 一种可调节人体尿酸的植物提取组合物及其制备方法 |
Non-Patent Citations (1)
Title |
---|
叶锦先等: "《痛风患者宜吃食物》", 30 September 2017, 金盾出版社 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113679051A (zh) * | 2021-08-24 | 2021-11-23 | 广州丹荟生物科技有限公司 | 一种牡丹多肽粉、其固体饮料及应用 |
CN114209049A (zh) * | 2021-12-20 | 2022-03-22 | 金日制药(中国)有限公司 | 一种海洋益生元组合物及其制备方法和用途 |
CN115104734A (zh) * | 2022-07-19 | 2022-09-27 | 中山市嘉信医疗器械有限公司 | 一种降尿酸保健食品及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109452521B (zh) | 一种辅助降尿酸肽固体饮料、制备方法及用途 | |
CN110916200A (zh) | 一种降尿酸组合物及其制备方法 | |
CN106261763A (zh) | 一种谷物膳食纤维代餐粉及其制备方法 | |
CN101507494A (zh) | 高血脂高血压患者用的特殊膳食用食品 | |
CN105727081A (zh) | 一种用于治疗痛风的保健品组合物 | |
CN104208654A (zh) | 一种以地龙蛋白提取物为主的保健配方 | |
CN101238893B (zh) | 一种高膳食纤维鹰嘴豆营养粉及其制备方法和用途 | |
CN105412623A (zh) | 治疗脂肪肝、***炎、肾痛肾炎、高血压及糖尿病的药物 | |
CN106036342A (zh) | 适合于糖尿病人群食用的膳食补充固体饮料及其制备方法 | |
CN102258686B (zh) | 预防和治疗心脑血管病的中药制剂 | |
CN112791175A (zh) | 提高人体新陈代谢机能和排出代谢废物的中西药组合物及其制备方法 | |
CN112753815A (zh) | 一种青砖茶饮品及其制备方法 | |
CN105077429A (zh) | 一种女性养颜美容饮料 | |
KR20080090808A (ko) | 피부미용을 위한 건강보조식품의 조성물 | |
CN101129956B (zh) | 一种治疗佝偻病的中药 | |
CN102258628A (zh) | 一种具有促进排铅作用的中药组合物 | |
CN104585634A (zh) | 一种降压降脂米饼及其制作方法 | |
CN101224005B (zh) | 一种具有全营养补充功效的营养片剂及其生产方法 | |
CN104800690B (zh) | 一种降尿酸的中药及其制备方法 | |
CN102228575A (zh) | 治疗高血压的外用药物及其生产方法 | |
CN114848699A (zh) | 一种具有降尿酸功效的组合物及其制备方法和应用 | |
CN108056461B (zh) | 一种黑木耳润肠功能咀嚼片及其制备方法 | |
CN102988747B (zh) | 一种三刺降三高的冲剂及其制备方法 | |
CN108936173A (zh) | 一种益中年男性肽复配的固体饮料及其制备方法 | |
CN112076305A (zh) | 一种治疗人体代谢症候群及杀菌消炎的中药制内服外用原液合剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200327 |
|
RJ01 | Rejection of invention patent application after publication |